| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Bionano Genomics, Inc. (NASDAQ:BNGO), today announced the publication of a special issue of Cancers journal entirely dedicated to the Company's optical genome mapping (OGM) workflow. The issue, which features guest editors Dr. Adam Smith from University of Toronto, Dr. Gordana Raca from Children's Hospital Los Angeles, and Dr. Alexander Hoischen from Radboud University Medical Center, includes eight peer-reviewed publications, with three additional publications expected to come, covering the use of OGM in hematological malignancy research and demonstrating its potential to offer significant research insights in a simple and effective workflow.
In an editorial, Drs. Smith, Raca and Hoischen describe the advantages OGM has over traditional cytogenetic methods of analysis, including karyotyping (KT), fluorescence in situ hybridization (FISH), and chromosomal microarray analysis (CMA), such as higher resolution and the ability to detect impactful structural variants (SVs). The guest editors also discuss limitations of long and short-read sequencing for SV detection, including challenges with resolution, sensitivity, throughput, achieved coverage, and price per genome. The guest editors note that OGM offers benefits for laboratory adoption, due to its cost-efficient and easily scalable workflow and simple analysis pipeline and software system. They conclude that OGM could enable "next generation cytogenetics" due to its potential to replace traditional cytogenetic methods and detect variants that may increase the understanding of hematologic malignancies and further expand hematological research.
The issue's other publications, authored by researchers from the United States, Canada, Germany, Finland, and a consortium of Spanish laboratories, cover research indications including acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), myeloma and myeloid cancers. These publications include findings that demonstrate OGM's high level of concordance with traditional methods for the detection of SVs, ability to identify additional pathogenic SVs missed by those methods, contributions to comprehensive tumor profiling, and potential to influence disease classification and risk prognostication.
"I personally believe the importance of OGM for hematological malignancies research cannot be overstated. What I have seen over my career as a molecular cytogeneticist is that oncologists need more information. The papers published in this dedicated issue elegantly illustrate how information provided by OGM surpasses the capabilities of the current tools in cancer research. I want to congratulate the co-editors on creating such an impactful compilation of important research results and original papers," commented Alka Chaubey, PhD, FACMG, chief medical officer of Bionano.
"This special edition of Cancers dedicated to OGM is a significant milestone for the technique and for people in the various fields of genome analysis who are looking for ways to move the community forward. We were pleased to see the guest editors and publication authors share findings that underscore OGM's potential to replace traditional cytogenetic methods and show that OGM offers significant benefits that sequencing can't offer. We agree with the editors' note that OGM is a powerful tool in the cytogenetics repertoire that may contribute to the growth and relevance of the field," stated Erik Holmlin, PhD, president and chief executive officer of Bionano.
The publication can be found here.
Posted In: BNGO
